Dr. Ying Chi, Co-founder, CEO & CTO of JiaoJing Biotech, to Speak at 2023 Zhongguancun Life Science Park Innovation Summit on AI-Driven Macromolecular Drug Discovery
Seizing the historic opportunities presented by the new wave of technological revolution and industrial transformation, Zhongguancun Life Science Park, as a key pillar of Beijing’s “Three Cities and One District” master platform for building an international science and technology innovation hub, has invested in and attracted numerous biotechnology innovation platforms, fostering agglomeration advantages across the upstream and downstream segments of the industry chain.On March 24, 2023, Zhongguancun Life Science Park Co., Ltd. joined forces with multiple technology platforms to co-host the “2023 Zhongguancun Life Science Park Technology Platform Industry-Research Innovation Summit.”, focusing on core areas such as “AI-enabled new drug development,” “breaking through undruggable targets,” “biotech drug evaluation,” and “clinical biospecimen biobanking and utilization,” we bring together industry leaders, investment experts, and entrepreneurs from leading and innovative enterprises to pool diverse strengths and insights. By integrating the entire chain of industry, academia, research, and application, we aim to promote the establishment of a novel, multi-tiered, broad-spectrum, functional, and open support system for innovative technology platforms.
Chi Ying, Co-founder, CEO & CTO of Jiaojing (Beijing) Biotechnology Co., Ltd. Confirmed attendance at the AI-Enabled Innovative Drug R&D Forum, part of the 2023 Zhongguancun Life Science Park Technology Platform Industry-Research Innovation Summit, and will deliver a presentation on the topic “R&D and Practice of AI-Driven Innovative Macromolecular Drugs.”
Ph.D. in Bioengineering from Imperial College London; Postdoctoral Fellow in Biomedical Engineering at the University of Oxford; Expert contributor to the drafting of the 14th Five-Year Plan Fund Guidelines for the Integration of Biology and Information Technology, issued by the Ministry of Science and Technology of China; Doctoral Supervisor at Nanyang Technological University (Singapore) and Zhejiang University; Local/Online Chair of the ACM Multimedia Conference (ACM MM 2021).。Served as the founder and head of the Intelligent Pharmaceutical Department at Alibaba DAMO Academy, and hosted the Alibaba Tianchi Cryo-EM Protein Structure Modeling Competition and the Broad-Spectrum Antibody Drug Design Competition for Novel Coronavirus. Published nearly 100 international papers, patents (including pending applications) in China and abroad, and professional book chapters.Research areas cover cutting-edge artificial intelligence technologies for macromolecular drug development, including antibody design, neoantigen discovery, cryo-EM protein structure modeling, protein structure prediction, and single-cell spatial transcriptomics.
Since its inception, Jiaojing Bio has been dedicated to leveraging innovative technologies such as artificial intelligence and omics big data to accelerate drug discovery and validation. The company integrates its AI algorithm team, a seasoned large-molecule drug R&D team, and high-throughputBy organically integrating the quantitative wet-lab experimental platform, we have fully developed Neo One, a new-generation AI-powered macromolecular drug discovery platform. This platform assists pharmaceutical companies in rapidly conducting drug target identification and screening, exploring mechanisms of drug action, and optimizing macromolecular drugs such as specific antibodies.
AIEmpowering Innovative Drug R&D Forum
In recent years, both artificial intelligence (AI) and biotechnology have achieved leapfrog developments in their respective fields. The advancement of deep learning has ushered in a new era for AI technology, resolving long-standing bottlenecks that have plagued academia, such as protein structure prediction. Meanwhile, the rapid progress of various omics technologies, exemplified by second-generation high-throughput sequencing and cryo-electron microscopy, has provided robust data generation capabilities, laying a solid foundation for algorithm training and optimization. Currently, AI is involved in every stage of biomedical development. With further technological advancements and breakthroughs, AI is poised to bring about disruptive changes to new drug research and development, offering broad prospects for the future.
This forum will invite AI companies, pharmaceutical companies, and investors to discuss innovative drug development empowered by AI.
Core Issues
1. AI-Driven mRNA Drug Design Platform
2. Potential Applications of Computational Protein Design in Biotechnology
3. Cloud Computing Accelerates Life Sciences
4. Applications of Generative Artificial Intelligence in Drug Discovery and Development
5. From Natural to Synthetic, and Then to Intelligent
6. Research and Development and Practice of AI-Driven Innovative Macromolecular Drugs
7. Commercialization of AI-Enabled Drug Discovery
1Zhongguancun Life Science Park and Six Major Innovation Technology Platforms Issue a Joint Statement
This summit is organized byUnder the guidance of the Administrative Committee of Zhongguancun Life Science Park, Zhongguancun Life Science Park Company, Zhongguancun Life Science Park Incubator Company, and Changfazhan Company have joined forces with six core biotechnology innovation platforms: the Zhongguancun AI New Drug R&D Platform, the Beijing Public Service Platform for Clinical Data and Sample Resources, the Cryo-EM Platform, the High-Resolution Mass Spectrometry Omics Platform, the Biopharmaceutical Evaluation Platform, and the Integrated Biological CRO Services Platform., by focusing on core aspects of pharmaceutical R&D such as basic research, target discovery, pilot-scale development, and drug analysis, we can further unlock the industry's potential, better foster the continuous growth of emerging business models, and promote high-quality development in the field of life sciences and technology.
2Exploring Forward-Looking Trends in Biotechnology and Life Sciences Through Multi-Format Dialogues
AsThe Inaugural Grand Event Co-hosted by Zhongguancun Life Science Park and Its Technical Platform, this summit is themed1 Main Forum + 4 Thematic Sub-forumsThe forum format ensures greater depth, breadth, cutting-edge relevance, and richness of resources. The main forum will serve as a central platform for showcasing the insights of industry participants, with numerous leading experts engaging in aOn Biotechnology Across Multiple Fields, Including Laboratory Animals and Viral Infections"brainstorming." The sub-forum focuses on "High-Quality Development and Sustainable Growth of Biobank Resources”、““AI-Empowered Innovative Drug R&D,” “Breaking Through Undruggable Targets,” “Biologic Drug Evaluation”In-Depth Analysis of the Innovation and High-Quality Development Pathways and Strategies for Biopharmaceutical Technology Across Four Major Dimensions.
3Top Industry Leaders Gather; Deep Engagement from the Pharmaceutical Vertical Audience
CompilationOver 40 distinguished guests, including national academicians, heads of regulatory agencies, leading academics, executives of multinational pharmaceutical companies, directors of Grade A tertiary hospitals, and senior investors, spanning the six major sectors of government, industry, academia, research, healthcare, and investment., converging new ideas, new technologies, and new business models; focusing on pressing industry issues; jointly seeking truth and insights; and conducting comprehensive, high-level, high-quality, and forward-looking sharing and discussions.
For more conference details, please scan the QR code to follow.